Table 1

Summary estimates for intraocular pressure at 3 months derived from the pairwise meta-analysis

ControlExperimentalTotal no of studiesMean
difference*
95%CIτ2I2
LowUp
PlaceboBimatoprost 0.01%14.605.603.60NANA
Latanoprost13.103.982.22NANA
Unoprostone1−0.30−1.500.90NANA
Betaxolol23.164.172.150.352%
Brimonidine12.303.990.61NANA
Brinzolamide12.223.480.96NANA
Dorzolamide42.483.841.121.376%
Levobunolol27.908.946.850.00%
Timolol43.754.752.760.658%
Bimatoprost 0.01%Latanoprost21.020.681.370.00%
Tafluprost12.30−0.915.51NANA
Travoprost21.50−1.984.975.280%
Bimatoprost 0.03%Latanoprost70.990.461.530.361%
Travoprost80.44−0.521.401.486%
LatanoprostLatanoprostene bunod11.231.760.70NANA
Tafluprost30.991.920.070.00%
Unoprostone62.902.163.630.337%
Travoprost7−0.15−1.301.001.987%
ApraclonidineTimolol2−0.44−3.913.035.689%
BetaxololLatanoprost21.843.220.470.00%
Unoprostone10.600.091.11NANA
Dorzolamide2−0.21−0.820.400.00%
Levobunolol2−4.65−10.130.8413.384%
Timolol61.302.460.131.267%
BrimonidineLatanoprost51.222.130.310.878%
Betaxolol12.000.903.10NANA
Brinzolamide20.900.391.420.00%
Timolol40.420.040.810.00%
Travoprost1−1.20−3.771.37NANA
BrinzolamideDorzolamide2−0.34−0.840.160.00%
CarteololLevobunolol12.904.591.21NANA
Timolol4−0.27−1.110.570.460%
DorzolamideLatanoprost1−2.90−3.70−2.100.0NA
LevobunololTimolol90.11−0.400.620.115%
TimololBimatoprost 0.03%62.062.361.750.00%
Latanoprost151.181.650.700.676%
Latanoprostene bunod21.421.841.010.00%
Tafluprost2−0.50−1.120.120.138%
Unoprostone20.94−0.432.310.987%
Brinzolamide31.100.521.690.00%
Dorzolamide40.990.341.640.126%
Travoprost40.891.260.520.00%
TravoprostTafluprost1−1.30−2.930.33NANA
Total16 drugs138§
  • Embedded Image, PGA

  • *Difference between the reduction in IOP during the study of the experimental drug and the control drug (mean difference under 0 favours the experimental drug). Results presented in bold are significant.

  • †τ2 describes the underlying between-study variability.

  • ‡I2 is the percentage of variability in the treatment estimates which is attributable to heterogeneity.

  • §106 trials considered: 93 two-arm trials, 11 three-arm trials and 2 four-arm trials.

  • IOP, intraocular pressure; NA, not available; PGA, prostaglandin analogue.